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Objetivo: valorar la incidencia de hiperglicemia, hipertrigliceridemia y alteraciones de los parámetros bioquímicos hepáticos (PBH) en pacientes 
mayores de 65 años frente a pacientes más jóvenes con nutrición parenteral (NP). El objetivo secundario fue comparar la incidencia de cualquiera 
de los tres eventos.
Material y métodos: se incluyeron adultos no críticos hospitalizados que recibieron NP durante siete días o más en 15 hospitales españoles. 
Se excluyeron pacientes con hiperglicemia, hipertrigliceridemia, alteración de los PBH, sepsis, shock, cirugía biliopancreática, insuficiencia renal, 
diabetes tipo 1 o tipo 2 insulinodependiente, complicaciones diabéticas agudas y obesidad previas a la NP. Los pacientes se clasificaron en dos 
grupos: YOUNG (35-64 años) y OLD (65-95 años).
Resultados: se incluyeron 200 pacientes; 63 (31,5%) en el grupo YOUNG y 137 (68,5%) en el OLD. Se detectó hiperglicemia en 37 (18,5%) 
pacientes, ocho (12,7%) en el grupo YOUNG y 29 (21,2%) en el OLD (p = 0,174). Solo hubo un caso (0,7%) de hipertrigliceridemia. Alteraciones 
de PBH aparecieron en 141 (70,5%) pacientes, 44 (69,8%) en el grupo YOUNG y 97 (70,8%) en el OLD (p = 1,000). El modelo para hiperglicemia 
incluyó como variables diabetes tipo 2, cirugía previa y el uso de medicamentos hiperglucemiantes. El modelo para alteración de PBH incluyó 
cirugía previa, dosis de lípidos y aminoácidos y medicaciones hepatotóxicas. Hubo una tendencia a menor alteración por la edad. El modelo global 
para cualquier evento incluyó cirugía previa, diabetes tipo 2 y medicaciones que causen las alteraciones estudiadas.
Conclusión: los pacientes de 65 años o más que recibieron NP tuvieron incidencias similares de hiperglicemia, hipertrigliceridemia y alteración 
de PBH a las de los pacientes más jóvenes. Hubo una tendencia a menor alteración de PBH en los pacientes mayores.
Abstract 
Objective: this study assessed the incidence of hyperglycemia, hypertriglyceridemia, and liver function test (LFT) alterations among patients older 
and younger than 65 years receiving parenteral nutrition (PN). A secondary objective was to compare the incidence of any of these three events.
Material and methods: inclusion criteria were non-critically ill adult inpatients receiving PN for ≥ 7 days in 15 hospitals in Spain. Exclusion 
criteria were hyperglycemia, hypertriglyceridemia, LFT alterations, sepsis, shock, pancreatic/hepatobiliary surgery, renal failure, diabetes mellitus 
(DM) type 1, insulin-treated DM type 2, acute DM complications, or obesity prior to PN. Patients were classified into groups YOUNG (aged 35-64) 
and OLD (aged 65-95).
Results: this study recruited 200 patients. Group YOUNG included 63 (31.5%) patients and OLD, 137 (68.5%). Hyperglycemia appeared in 37 
(18.5%) patients, eight (12.7%) in group YOUNG and 29 (21.2%) in group OLD (p = 0.174). Hypertriglyceridemia appeared in only one (0.7%) 
patient. LFT alterations appeared in 141 (70.5%) patients, 44 (69.8%) in group YOUNG and 97 (70.8%) in group OLD (p = 1.000). The model for 
hyperglycemia included DM type 2, previous surgical procedure, and use of hyperglycemia-inducing medications. The model for LFT alteration 
included previous surgical procedure, amount of lipids and amino acids, medications causing LFT alterations and a trend for age group. The 
model for any event included surgical procedure, DM type 2, and medications causing alterations.
Conclusion: patients of ≥ 65 years receiving PN had similar incidences of hyperglycemia, hypertriglyceridemia, and LFT alterations as younger 
patients. Additionally, older patients had trends toward lower LFT alterations.
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INTRODUCTION
Life expectancy has increased steadily in developed countries 
during the last century and the health status of people aged ≥ 65 
years is therefore of growing importance. This age group is known 
to present increased risk of several diseases that are associated 
with greater use of health resources. Currently, older age is not 
a contraindication for surgical procedures (1,2) or for admission 
to intensive care units (ICU) (3), but older patients do experience 
more surgical complications and have increased risk of adverse 
outcomes (1,3). Older age is also not a contraindication for par-
enteral nutrition (PN) (4). To our knowledge, no specific studies 
have been published on the prevalence of PN support in older 
patients in comparison to younger patients in general hospitals. In 
a retrospective-cohort study on critically-ill adult patients in 125 
USA hospitals, PN usage declined slightly and similarly, around 
6%, over time in all age groups, including elderly patients, during 
an eight-year period (5). A cross-sectional study on PN use over 
three months in 15 acute care hospitals in the north of England 
found that patients receiving PN had a median age > 65 years 
(6). Thus, older patients seem to be exposed to PN in at least 
the same proportions as younger patients. However, few studies 
have assessed the effect of PN in the elderly compared to young 
patients (7,8). These retrospective studies did not find differences 
in nutritional and inflammatory markers, biochemical outcomes 
and associated morbidity of PN when compared to younger con-
trols. However, older patients may present metabolic alterations 
during PN as diminished plasma lipoprotein-lipase activity (9), limit-
ed capacity to mobilize fat stores (10), and lower glucose oxidation 
(11) or have comorbidities that could increase PN complications (4).
The main purpose of this study was to assess metabolic com-
plications of PN, comparing the incidence of adverse events 
(hyperglycemia, hypertriglyceridemia, and liver function test 
[LFT] alterations) in non-critically ill adult inpatients receiving PN 
between those patients ≤ 64 years and those ≥ 65. A secondary 
purpose was to compare the incidence, as a first appearance, 
of any of these three adverse events, as a variable of overall 
metabolic complications between the two groups.
MATERIAL AND METHODS
A retrospective analysis of a prospectively collected data set was 
performed on a cohort of medical and surgical non-critically ill adult 
inpatients receiving PN in 15 hospitals in Catalonia (Spain) from 
January 1st 2014 to December 31st 2014. The study was reviewed 
and approved by the ethics committees of Hospital Universitari 
Sagrat Cor, Parc de Salut Mar, and Hospital Clínic de Barcelona, 
Spain. The rest of the hospitals adhered to these approvals.
PATIENTS
Patients were classified into two groups depending on age: 
group YOUNG included adult patients aged between 35 and 
64 years (middle age and older adulthood), and group OLD, senior 
patients aged between 65 and 95 years (younger and older old 
age). They were followed-up until PN was discontinued for any 
reason or oral or enteral nutrition started, or they were admitted 
to ICU or to Post-Anesthesia Care Unit (PACU) for three days or 
longer, or were transferred to another hospital.
INCLUSION AND EXCLUSION CRITERIA
Patients who entered the study met the following inclusion cri-
teria: non-critically ill, recent weight available, and PN duration 
longer than six days. In addition, PN, including peripheral PN con-
taining lipid emulsions, had to be the unique source of nutritional 
support covering at least 80% of the equation-calculated resting 
energy expenditure (cREE) (12).
The following acute conditions at the beginning of PN were 
exclusion criteria: sepsis; hypovolemic or cardiogenic shock; renal 
failure with a calculated glomerular filtration rate (cGFR) < 30 ml/
min/1.73 m2 (13); triglyceridemia > 250 mg/dl; any LFT (total bili-
rubin, aspartate aminotransferase [AST], alanine aminotransferase 
[ALT], gamma glutamyl transferase [GGT], or alkaline phosphatase 
[ALP]) value > 1.5-fold the upper limit of normal range (ULN); a 
glycemia test > 180 mg/dl 24 hours before the beginning of PN; 
biliary or hypertriglyceridemia-induced pancreatitis; and admis-
sion due to hyperosmolar hyperglycemia, diabetic ketoacidosis, 
or hypoglycemia under 70 mg/dl. Chronic conditions considered 
as exclusion criteria were: chronic liver disease, hepatobiliary dis-
ease, diabetes mellitus type 1, insulin-treated diabetes mellitus 
type 2, and body mass index (BMI) > 35 kg/m2. Patients were 
also excluded if they underwent biliopancreatic or liver surgical 
procedures, or they were admitted for longer than three days to 
ICU or PACU within the first 72 hours of PN course.
VARIABLES
Main outcomes were the comparison of the incidence of hyperglyce-
mia, hypertriglyceridemia, and LFT alterations between the two groups 
defined above. The secondary variable was defined as the combined 
variable of the presence of any of the above-mentioned complications 
(hyperglycemia, hypertriglyceridemia, or LFT alterations).
Hyperglycemia was defined as capillary or plasma glycemia 
≥ 180 mg/dl. If it was registered by capillary test, it had to be 
measured at least twice daily. Hypertriglyceridemia was defined as 
plasma triglycerides > 400 mg/dl. LFT alteration was defined as 
any liver enzyme increase > 2-fold the ULN, conjugated bilirubin 
> 2 mg/dl, or total bilirubin > 2.5 mg/dl. Blood clinical chemistry 
parameters were obtained at least once weekly.
DATA COLLECTED
At the beginning of the study, data collected were demograph-
ics (sex, age, and BMI), main diagnosis, ward area (medical, sur-
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gical or trauma), date of surgical procedure if relevant, Charlson 
comorbidity index (14), indication for and date of PN initiation, 
and cREE calculated by the Mifflin-St Jeor equation (12). Addi-
tional data were registered when any alteration in main variables 
was detected and at the end of PN: amounts of macronutrients 
(amino acids, glucose, and lipids) delivered in PN, and the ratio 
of kilocalories provided by PN and cREE; biochemical parameters 
(glycemia, triglyceridemia, albumin, creatinine, total bilirubin, con-
jugated bilirubin, AST, ALT, GGT, ALP); ICU or PACU admission for 
three days or longer; the reason for PN discontinuation when it 
occurred, and PN duration. As overall health outcomes, hospital 
length of stay (LOS) and mortality during hospital admission were 
recorded.
As the co-administration of some medications might alter the 
variables studied, the number of medications affecting glycemia, 
triglyceridemia, or LFTs was collected when they were adminis-
tered for at least three days during PN. A list of medications to 
be monitored relating to hyperglycemia (nine medications) (15), 
hypertriglyceridemia (12 medications) (16), and LFT alterations 
(53 medications) was obtained from several sources (17-19).
PARENTERAL NUTRITION
PN was prepared following usual hospital practices as an 
“all-in-one” admixtures containing amino acids, glucose and 
lipid emulsions. They were administered in a 24-hour perfusion 
through central catheters or peripheral lines.
STATISTICAL ANALYSIS
Descriptive statistics were reported by age category. Continuous 
variables were reported as mean ± standard deviation (SD), and 
categorical variables were reported as frequency and percent. 
To assess for equivalency between groups, continuous variables 
(age, Charlson comorbidity index, BMI, kilojoules from PN) were 
compared using Student’s t-tests. The categorical variables (sex 
and admission diagnosis category) were compared using the Chi-
squared test or Fisher’s exact test.
Unadjusted incidence rates of complication outcomes (hyper-
glycemia, hypertriglyceridemia, and LFT alterations) were reported 
by age group. Using an adjusted Cox proportional hazard model, 
age categories were compared with regard to each complication 
outcome assessed (hyperglycemia, hypertriglyceridemia, and LFT 
alteration). Potential factors associated with the occurrence of 
each complication outcome studied were evaluated by the use of 
univariate analysis. For each complication assessed, variables with 
a two-tailed p-value below 0.10 in the univariate analysis or those 
that were deemed clinically relevant were selected for inclusion in 
a multivariate Cox proportional hazard model to identify variables 
associated with occurrence of the complication evaluated. The 
final model was determined using backward elimination variable 
selection (Wald statistic). The initial model contained all the inde-
pendent variables selected.
In the same way, the secondary outcome was assessed by 
adding all potential factors found in a multivariate Cox proportional 
hazard model to identify variables associated with the occurrence 
of any of the complications studied.
Additional analyses were performed to compare the rate of 
patients free of any adverse event over time (Kaplan-Meier plot) 
between groups.
In all analyses, p values were two-tailed, and a p < 0.05 was 
considered as statistically significant. SPSS Version 12 statistical 
software for Microsoft Windows (SPSS Inc., Chicago, IL, USA) was 
used for all analyses.
RESULTS
This study recruited 200 patients. Group YOUNG included 63 
(31.5%) patients and group OLD, 137 patients (68.5%). Both 
groups differed in several baseline parameters (Tables I and II). 
Group OLD presented lower cREE, cGFR, triglycerides, cholesterol, 
and albumin, but higher Charlson comorbidity index. This group 
received smaller amounts of macronutrients, but the same ratio 
of kilocalories provided/cREE during a similar period.
Hyperglycemia was detected in 37 (18.5%) patients, eight 
(12.7%) in group YOUNG, and 29 (21.2%) in group OLD 
(p = 0.174). Surgical patients showed greater rates of hyper-
glycemia and LFT alterations than non-surgical patients. Hyper-
triglyceridemia appeared in only one (0.7%) patient in group 
OLD. LFT alterations were detected in 141 (70.5%) patients, 
44 (69.8%) in group YOUNG and 97 (70.8%) in group OLD 
(p = 1.000). Patients with LFT alterations showed differences in 
baseline cGFR, albumin, and ALP, and amounts of glucose and 
amino acids administered compared with those without alter-
ations. Complication outcome incidence rates and differences 
found are listed in table III.
Table IV shows hazard ratios for hyperglycemia and LFT alter-
ations, both adjusted for age group, surgical procedure, and med-
ication use. Multivariate Cox models were additionally adjusted for 
differences found: for the hyperglycemia model, and for diabetes 
mellitus type 2 and amount of glucose administered. For the liv-
er-function-test-alteration model, adjustments were for baseline 
FA, albumin, cGFR and amount of macronutrients administered. 
The final model for hyperglycemic events included diabetes mel-
litus type 2, surgical procedures, and use of medications that 
increase glycemia. For LFT alterations, the final model included 
surgical procedures, amounts of lipid and amino acid adminis-
tered, use of more than one medication related to liver alteration, 
and age group.
The Cox proportional hazards regression for predictor variables 
on secondary outcome (the incidence of any of the three adverse 
events) found three variables as significant predictors: surgical 
procedure, diabetes mellitus type 2, and use of medications 
causing hyperglycemia, hypertriglyceridemia, or LFT alterations 
(Table IV). Amino acid amounts were also included in the final 
model. Since only one patient showed hypertriglyceridemia, no 
statistical analysis was performed for this complication.
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Adverse events were detected at day 6.01 ± 3.99 without dif-
ferences between groups (p = 0.952). Hyperglycemia appeared 
at day 4.68 ± 4.45; the only hypertriglyceridemia was detected at 
day 7 and LFT alterations appeared at day 6.79 ± 4.12.
Amongst those patients who suffered adverse events, patients 
of group OLD had the same number of days of PN (12.91 ± 7.48 
vs 13.85 ± 6.66; p = 0.462), LOS (27.01 ± 16.41 vs 28.11 
± 13.82; p = 0.691) and mortality (10/104 vs 2/4; p = 0.343) 
as those of group YOUNG.
There was no difference in the rates of patients free of any 
adverse event over time between the two groups (p = 0.808) as 
shown by the Kaplan-Meier curve in figure 1.
There were no differences between groups in the rates of inci-
dence of variables from the beginning to the end of PN except 
for triglyceridemia, which increased more in group OLD (Table V).
DISCUSSION
In our study, older patients did not present a greater incidence 
of metabolic complications during PN than younger patients. In 
addition, older age was not related to the appearance of adverse 
events. In our patients, the main predictors for the adverse events 
studied were surgical procedures, diabetes mellitus type 2, and 
the concomitant use of medications related to metabolic disorders.
Our findings were in accordance with previous studies reporting 
no differences between older and younger non-critically ill patients 
receiving PN (7,8). Nonetheless, differences were found on baseline 
characteristics as well as amount of nutrients administered between 
the two groups assessed. However, differences found have been 
assessed with regression models in order to manage them.
In an early study, aging was reported to increase glycemia 
during PN in a heterogeneous cohort including critically-ill patients 
(20) but rates of hyperglycemia were not assessed. Diminished 
insulin response in the injured elderly might have contributed to 
this finding (20). In a study on a cyclic 6-hour PN regimen with 
high energy low protein content, glucose oxidation was about 
30% lower and glycemia was about 20% higher with comparable 
insulinemia in elderly patients when compared with middle-aged 
patients (11). 
Table I. Patients’ diagnoses and 












Lower gastrointestinal tract 
neoplasm
14 (22.2%) 54 (39.4%) 0.074
Non-neoplasm 
gastrointestinal disease
9 (14.3%) 23 (16.8%)
Upper gastrointestinal tract 
neoplasm
10 (15.9%) 21 (15.3%)
Inflammatory bowel disease 7 (11.1%) 9 (6.6%)
Others 23 (36.5%) 30 (21.9%)
Parenteral nutrition indication
Post-operative ileus 13 (20.6%) 54 (39.4%) 0.066
Intolerance to oral or enteral 
feeding
11 (17.5%) 21 (15.3%)
Small-bowel occlusion 13 (20.6%) 15 (10.9%)
Other post-operative 
complications
6 (9.5%) 15 (10.9%)
Others 20 (31.7%) 32 (23.4%)











Age, years 52.19 ± 7.62 76.77 ± 6.53 < 0.001
BMI, kg/m2 24.86 ± 4.08 25.54 ± 3.69 0.240
cREE, kcal/kg/day 20.6 ± 1.9 18.7 ± 2.0 < 0.001
Charlson comorbidity 
index, points
2.95 ± 2.48 5.50 ± 4.25 < 0.001
Creatinine, mg/dl 0.70 ± 0.26 0.85 ± 0.28 0.001
cGFR, ml/min/1.73 m2 104.1 ± 18.9 78.4 ± 17.9 < 0.001
Glycemia, mg/dl 112 ± 24 114 ± 28 0.570
Total bilirubin, mg/dl 0.47 ± 0.26 0.47 ± 0.27 0.998
ALT, U/l 19.5 ± 13.6 19.0 ± 13.0 0.815
AST, U/l 19.0 ± 10.0 20.8 ± 10.1 0.274
GGT, U/l 43.2 ± 24.5 37.6 ± 23.5 0.137
ALP, U/l 72.2 ± 29.9 74.0 ± 23.8 0.640
Triglycerides, mg/dl 127.1 ± 50.2 108.2 ± 43.0 0.008
Cholesterol, mg/dl 120.7 ± 44.2 101.9 ± 38.6 0.009
Total protein, g/dl 5.24 ± 0.83 4.97 ± 0.89 0.119
Albumin, g/dl 2.96 ± 0.58 2.57 ± 0.65 < 0.001
PN characteristics
Amino acids, g/kg/day 1.24 ± 0.03 1.06 ± 0.23 < 0.001
Glucose, g/kg/day 3.07 ± 0.77 2.77 ± 0.58 0.002
Fat, g/kg/day 0.81 ± 0.29 0.78 ± 0.22 0.502
kcal/kg/day 25.33 ± 6.8 23.15 ± 4.7 0.009
Ratio kcal provided/
cREE
1.23 ± 0.30 1.25 ± 0.26 0.679
Days of PN 14.1 ± 8.0 12.7 ± 7.2 0.208
ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate 
aminotransferase; BMI: body mass index; cGFR: calculated glomerular filtration 
rate; GGT: gamma glutamyl transferase; cREE: resting energy expenditure.
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In a more recent study to determine the prevalence of diabetes, 
prediabetes, stress hyperglycemia, and factors affecting hyper-
glycemia (> 180 mg/dl) in non-critically ill patients receiving PN, 
age ≥ 65 years showed a significant relationship to the develop-
ment of hyperglycemia compared with younger age groups (21). 
However, age was not found to be a factor for hyperglycemia in 
the present study maybe because we excluded diabetes mellitus 
type 1 and insulin-treated diabetes mellitus type 2 patients. This 
discrepancy could be also related to the glucose doses received. 
Table III. Complication outcome incidence rates
Variable
Liver function test alteration p Hyperglycemia p
Yes No Yes No
Group YOUNG (≤ 64) 44 (69.8) 19 (30.2) 8 (12.7) 55 (87.3)
Group OLD (≥ 65) 97 (70.8) 40 (29.2) 1.000 29 (21.2) 108 (78.8) 0.174
Medications*
Yes 116 (76.8) 35 (23.2) 26 (32.1) 55 (67.99)
No 25 (51.0) 24 (49.0) 0.001 10 (9.3) 98 (90.7) < 0.001
Surgery
Yes 107 (76.4) 33 (23.6) 32 (22.9) 108 (77.1)
No 34 (56.7) 26 (43.3) 0.007 5 (8.3) 55 (91.7) 0.017
Amino acids, g/kg/day 1.05 (0.30) 1.16 (0.21) 0.010 1.08 (0.30) 1.12 (0.29) 0.498
Glucose, g/kg/day 2.74 (0.77) 2.97 (0.61) 0.033 2.71 (0.64) 2.87 (0.65) 0.188
Fat, g/kg/day 0.81 (0.47) 0.82 (0.19) 0.861 0.75 (0.18) 0.79 (0.26) 0.273
kcal/kg/day 23.28 (7.61) 24.76 (4.62) 0.167 22.71 (4.98) 23.97 (5.59) 0.208
ALT, U/l 19.59 (13.10) 18.06 (13.22) 0.455 22.10 (15.48) 18.47 (12.47) 0.129
AST, U/l 20.74 (10.29) 19.03 (9.37) 0.302 21.69 (10.11) 19.90 (10.02) 0.353
GGT, U/l 39.69 (23.79) 38.40 (24.44) 0.756 39.46 (22.87) 39.36 (24.16) 0.983
ALP, U/l 70.7 (20.8) 80.1 (34.4) 0.020 71.1 (21.1) 74.0 (26.8) 0.546
Total bilirubin, mg/dl 0.48 (0.26) 0.46 (0.27) 0.591 0.42 (0.19) 0.48 (0.29) 0.167
Albumin, g/dl 2.64 (0.60) 2.81 (0.75) 0.096 2.58 (0.5) 2.72 (0.7) 0.246
cGFR, ml/min/1.73 m2 84.4 (21.8) 91.5 (21.0) 0.036 84.3 (18.7) 87.0 (22.4) 0.490
*For the analysis, the presence of more than one medication affecting liver function tests or glycemia, depending on the statistical test, was considered. Variables 
presented as value (%) or value (±) depending on the variable shown. ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; 
cGFR: calculated glomerular filtration rate; GGT: gamma glutamyl transferase.
Table IV. Hazard ratios (HRs) for occurrence of liver function test alteration, hyperglycemia 
and any complication
Variable Hyperglycemia Liver function test alteration Any event
Age group (older) Not included, p = 0.74 0.69 (0.47-1.02), p = 0.06 Not included, p = 0.26
Medication use 3.47 (1.65-7.32)*, p < 0.01 1.86 (1.19-2.92)†, p < 0.01 1.59 (1.01-2.50)‡, p = 0.04
Surgery 3.27 (1.26-8.48), p = 0.02 1.86 (1.25-2.78), p < 0.01 2.04 (1.38-3.00), p < 0.01
Diabetes type 2 4.48 (2.11-9.51), p < 0.01 ---- 2.19 (1.25-3.82), p < 0.01
Amino acids, g/kg/day ----- 0.20 (0.09-0.44), p < 0.01 0.56 (0.28-1.10), p = 0.09
Fat, g/kg/day ----- 2.66 (1.50-4.73), p < 0.01 Not included, p = 0.61
Glucose, g/kg/day Not included, p = 0.36 Not included, p = 0.18 Not included, p = 0.81
Presented as hazard ratio (95% confidence interval). *Medications related to hyperglycemia. †Medications related to liver alterations. ‡Medications related to any of the 
events assessed (liver alteration or hyperglycemia).
Older and younger patients received similar glucose loads in these 
former studies. In our study, older patients received about 0.3 g 
of glucose/kg/day and about 2.18 kcal/kg/day less than younger 
patients. This is consistent with the fact that older patients have 
less cREE than younger patients (22,23), but our older patients 
received the same ratio of kcal provided/cREE as younger ones 
(Table II).
Studies on fat oxidation rates have shown inconclusive results 
in older adults compared to younger ones (23). 
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Specifically, older patients presented roughly 30% higher lipid 
oxidation, 35% higher FFA blood levels, and a lower respiratory 
quotient, but comparable triglyceridemia levels (11). In other study, 
older subjects presented higher FFA blood levels, about 65% lower 
lipoprotein lipase activity, and about 15% lower fat oxidation rates 
than younger patients, but triglyceridemia remained comparable 
in both groups. The authors concluded that elderly subjects can 
metabolize intravenous fat emulsions similarly to young individuals 
(9). In our study, at the end of PN, older patients showed higher 
triglyceridemia than younger patients while receiving a fat load of 
around 0.8 g/kg/day (Table V), but only one hypertriglyceridemic 
episode was detected. Our findings seem to be in agreement with 
the aforementioned studies, showing that older patients can main-
tain triglyceridemia levels similarly to younger patients, despite 
differences in fat oxidation. In contrast, in other study hypertri-
glyceridemia was detected in 36% of older patients (≥ 80 years) 
versus 8% in younger patients (< 80 years), but the authors did 
not show nutritional loads and mean triglyceridemia. Additionally, 
they defined hypertriglyceridemia as > 168 mg/dl whilst we set 
the cut-off point at 400 mg/dl in accordance with current Euro-
pean guidelines (24) and PN hypertriglyceridemia literature (25).
The influence of age has not been studied extensively in PN in 
association with liver alterations in adults. Reilly et al. found no dif-
ferences in maximum values of ALT, ALP, and bilirubin in patients 
< 80 years when compared to older patients. However, the group 
of older patients represented only 13% of the entire cohort (8). In 
a study using a cumulative logit model and including 162 patients 
receiving home PN for > 6 months, age was not a relevant factor 
in the development of liver disease (26). In another study on home 
PN, age was not a factor for chronic biochemical cholestasis in 
a cohort of 113 patients (27). Additionally, age was not a factor 
for liver dysfunction associated with specialized nutrition support 
in a prospective cohort of 725 critically ill patients (28). Indeed, 
in our study, age ≥ 65 showed a trend to a reduced incidence of 
this adverse event. We hypothesized that already diminished bile 
acid production and excretion, as occurs in older patients (29), 
could have been an influence in our findings.
Parenteral nutrition liver disease (PNALD) and LFT alterations 
associated to PN are considered to be of multifactorial origin and 
have a decreased incidence in adults compared to infants. Main 
factors in its development are excess caloric intake of macronu-
trients, specially fats, infectious or septic events, inflammation, 
oxidative stress, nutrient deficiencies, and contaminants in par-
enteral products (30). In general, our findings are in agreement 
with this knowledge: surgery as a pro-inflammatory factor and 
increased fat load.
Nevertheless, amino acid load has been found to reduce its 
incidence in our study. This parameter has not been studied exten-
sively in adults and usually has not been considered to play a role 
in PNALD currently (17). To our knowledge, only one prospective 
study found that a load > 1 g protein/kg/day was deleterious for 
liver parameters (31). The role of amino acid load in LFT alter-
ations during PN would require further studies.
In PN, the contribution of concomitant medications to adverse 
events has not been assessed in depth. The simultaneous use of 
some medications during PN has been shown to be of relevance 
for developing hyperglycemia (15,21) or hypertriglyceridemia (16), 
but we could not find studies for LFT alterations or PNALD. In our 
work, the simultaneous use of two or more medications has been 
associated with a moderate contributory influence in LFT alterations 
and a strong influence in hyperglycemia. These results on the effect 
of medications in PN toxicity warrant further investigation.
This is the first multicenter study that has evaluated the met-
abolic complications of PN in patients of ≥ 65 years compared 
to younger patients, but our study had several limitations. They 
include its observational design, and differences in amount of 
nutrients administered. Regression models adjusted by some of 
these limitations have been used to manage them. Besides, obser-
Figure 1. 
Comparison of the rate of patients free of any adverse event over time.
Table V. Evolution of variables during PN
Differences between final and 









Creatinine (mg/dl) -0.07 ± 0.1 -0.13 ± 0.29 0.065
Glomerular filtration rate, 
ml/min/1.73 m2
5.5 ± 11.2 9.2 ± 15.3 0.058
Glycemia, mg/dl 2.8 ± 29.0 3.8 ± 39.5 0.839
Total bilirubin, mg/dl -0.04 ± 0.30 -0.01 ± 0.26 0.458
ALT, U/l 24.3 ± 43.8 21.2 ± 48.8 0.664
AST, U/l 12.5 ± 28.4 15.9 ± 50.4 0.646
GGT, U/l 204.6 ± 274.0 178.9 ± 234.4 0.496
ALP, U/l 81.8 ± 97.8 75.9 ± 92.0 0.688
Triglyceridemia, mg/dl 31.0 ± 61.7 50.2 ± 56.8 0.035
ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate 
aminotransferase; GGT: gamma glutamyl transferase. 
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vational cohort studies can provide a reflection of daily clinical 
practices. The groups had several differences that replicated the 
differences that would be expected to be found between younger 
and older patients. Older patients have usually more comorbidities, 
worse renal function, and lower albuminemia.
Nutritional loads were different between the two groups, but 
both received the same amount of energy intake in relation to 
their cREE. This approach would be acceptable in our opinion. In 
clinical trials, it has been acceptable to use different medication 
doses in older people to reach the same efficacy (32). Critical-
ly-ill patients were not included in order to have a homogenous 
population, as well as to have a controlled number of variables 
to be adjusted for. Therefore, the results obtained could not be 
extrapolated to this group of patients. Finally, other PN safety vari-
ables, such as catheter-related infections, acid-base disturbances, 
metabolic bone disease, and other alterations were not assessed. 
We assessed the most prevalent adverse effects related to PN 
in hospitalized patients, since for less prevalent events a larger 
cohort would be needed.
In conclusion, non-critically ill inpatients of ≥ 65 years receiv-
ing PN had the same incidence of hyperglycemia, hypertriglyceri-
demia, and LFT alterations as younger patients when administered 
a caloric intake adapted to their cREE. In addition, the older age 
group may have a trend to a lower prevalence of LFT alterations 
related to PN.
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